Developer docs
API playgroundTry for free, no card

Search company profiles

Cellerys

Full company profile

uuid000omsq

Namestring
Cellerys
Legal namestring
Cellerys AG
Websiteurl
cellerys.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Cellerys AG is a clinical-stage Swiss biotechnology company founded in 2015 as a spinoff from the University of Zurich, developing CLS12311, an autologous cell therapy designed to induce antigen-specific immune tolerance in patients with relapsing remitting multiple sclerosis (RRMS). The therapy works by collecting a patient's own red blood cells, chemically coupling them ex vivo with twelve peptides representing the major target antigens in MS, and reinfusing them; the coupled cells then undergo natural apoptosis and are presented in a tolerogenic fashion in the liver and spleen, re-establishing immune tolerance without broadly suppressing the immune system. The product is being evaluated in the RED4MS Phase Ib/IIa trial across four European countries, with Phase Ib enrollment completed in December 2025 and Phase IIa preparation underway.

The company is pre-revenue and operates as a single-asset biotech with no disclosed pricing, licensing milestones, or commercial product. Its go-to-market model is the standard clinical-stage biotech pathway: advancing CLS12311 through regulated clinical trials with the goal of a future out-licensing, partnership, or trade sale. The company is headquartered in Schlieren (Zurich) with 11-50 employees, and is led scientifically by co-founders Roland Martin (CSO), Mireia Sospedra (Senior Principal Scientist), and Andreas Lutterotti (CMO), with Claudia Mitchell as Board Chair. Novartis holds a purchase option obtained through a June 2021 partnership that funded the Phase Ib program, and Wyss Zurich (a University of Zurich/ETH Zurich accelerator) provided early support. There are no disclosed venture capital rounds, institutional equity raises, or product revenue.

Short descriptiontext

Cellerys AG is a pre-revenue, clinical-stage Swiss biotech developing CLS12311, an autologous red blood cell-based immune tolerance therapy for relapsing remitting multiple sclerosis, currently advancing through the RED4MS Phase Ib/IIa trial in Europe.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSchlieren, Switzerland
HQ citystring
Schlieren
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
immune tolerance therapy, multiple sclerosis treatment, antigen-specific immunotherapy, peptide-coupled cell therapy, clinical-stage biotechnology
Industry2 codes
PRIMARYHLAKAIAF
Multiple Sclerosis & Neuroimmunology
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)
NAICS code2 codes
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
Multiple Sclerosis Therapy
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1CLS12311 Commercialization
TypeOne Time License
Description

Pre-revenue clinical-stage biotech company developing an immune tolerance therapy for multiple sclerosis. Revenue generation will depend on successful clinical development, regulatory approval, and commercialization of CLS12311.

cellerys.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cellerys is developing CLS12311, a clinical-stage autologous cell therapy for relapsing remitting multiple sclerosis in which a patient's red blood cells are collected, chemically coupled ex vivo with twelve peptides representing the major target antigens in MS, and reinfused to re-establish antigen-specific immune tolerance. The therapy is being evaluated in the RED4MS Phase Ib/IIa clinical trial across four European countries, with the Phase Ib last-patient visit completed in December 2025.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Cellerys is developing a single therapeutic product pipeline focused on immune tolerance induction for autoimmune diseases, specifically multiple sclerosis. The core product is CLS12311, a peptide-coupled red blood cell therapy where a patient's own RBCs are collected, coupled with specific peptides from target proteins associated with MS, and reinfused to restore immune tolerance. The RED4MS clinical trial is the development program for this therapy.

Product and service1 record
1CLS12311
CategoryMultiple Sclerosis Therapy
Description

Autologous red blood cells chemically coupled ex vivo with twelve peptides representing the major target antigens in multiple sclerosis, designed to induce antigen-specific immune tolerance in patients with relapsing remitting multiple sclerosis (RRMS) while leaving normal protective immune functions intact.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2024-01-01
Description

RED4MS Phase IB/IIA clinical study is conducted in 4 countries across Europe. Multiple clinical investigators and collaborators provide outstanding support for the first-in-human trial.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles9 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cellerys

Multiple Sclerosis Therapycellerys.com

Cellerys AG is a pre-revenue, clinical-stage Swiss biotech developing CLS12311, an autologous red blood cell-based immune tolerance therapy for relapsing remitting multiple sclerosis, currently advancing through the RED4MS Phase Ib/IIa trial in Europe.

What Cellerys does

Cellerys AG is a clinical-stage Swiss biotechnology company founded in 2015 as a spinoff from the University of Zurich, developing CLS12311, an autologous cell therapy designed to induce antigen-specific immune tolerance in patients with relapsing remitting multiple sclerosis (RRMS). The therapy works by collecting a patient's own red blood cells, chemically coupling them ex vivo with twelve peptides representing the major target antigens in MS, and reinfusing them; the coupled cells then undergo natural apoptosis and are presented in a tolerogenic fashion in the liver and spleen, re-establishing immune tolerance without broadly suppressing the immune system. The product is being evaluated in the RED4MS Phase Ib/IIa trial across four European countries, with Phase Ib enrollment completed in December 2025 and Phase IIa preparation underway.

The company is pre-revenue and operates as a single-asset biotech with no disclosed pricing, licensing milestones, or commercial product. Its go-to-market model is the standard clinical-stage biotech pathway: advancing CLS12311 through regulated clinical trials with the goal of a future out-licensing, partnership, or trade sale. The company is headquartered in Schlieren (Zurich) with 11-50 employees, and is led scientifically by co-founders Roland Martin (CSO), Mireia Sospedra (Senior Principal Scientist), and Andreas Lutterotti (CMO), with Claudia Mitchell as Board Chair. Novartis holds a purchase option obtained through a June 2021 partnership that funded the Phase Ib program, and Wyss Zurich (a University of Zurich/ETH Zurich accelerator) provided early support. There are no disclosed venture capital rounds, institutional equity raises, or product revenue.

Cellerys firmographics

Firmographics
Name
Cellerys
Legal name
Cellerys AG
Website
https://cellerys.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Cellerys AG is a pre-revenue, clinical-stage Swiss biotech developing CLS12311, an autologous red blood cell-based immune tolerance therapy for relapsing remitting multiple sclerosis, currently advancing through the RED4MS Phase Ib/IIa trial in Europe.
Ownership category
akta.pro rank

Cellerys industry classification

Industry
Product category
Multiple Sclerosis Therapy
NAICS
Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAKAIAF
Multiple Sclerosis & Neuroimmunology
SECONDARYHLAAABAL
Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods)
Healthcare & Life Sciences/Biotechnology & Biologics/Cell Therapy (autologous/allogeneic)

Keywords

  • Immune tolerance therapy
  • Multiple sclerosis treatment
  • Antigen-specific immunotherapy
  • Peptide-coupled cell therapy
  • Clinical-stage biotechnology

Where Cellerys is headquartered

Location

Headquarters

HQ city
Schlieren
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Cellerys business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

  1. CLS12311 Commercialization: Pre-revenue clinical-stage biotech company developing an immune tolerance therapy for multiple sclerosis. Revenue generation will depend on successful clinical development, regulatory approval, and commercialization of CLS12311.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Cellerys product offering

Product offering

Core offering

Cellerys is developing CLS12311, a clinical-stage autologous cell therapy for relapsing remitting multiple sclerosis in which a patient's red blood cells are collected, chemically coupled ex vivo with twelve peptides representing the major target antigens in MS, and reinfused to re-establish antigen-specific immune tolerance. The therapy is being evaluated in the RED4MS Phase Ib/IIa clinical trial across four European countries, with the Phase Ib last-patient visit completed in December 2025.

Product overview

Cellerys is developing a single therapeutic product pipeline focused on immune tolerance induction for autoimmune diseases, specifically multiple sclerosis. The core product is CLS12311, a peptide-coupled red blood cell therapy where a patient's own RBCs are collected, coupled with specific peptides from target proteins associated with MS, and reinfused to restore immune tolerance. The RED4MS clinical trial is the development program for this therapy.

Differentiator

Problem solved

Functional benefit

Products and services

  • CLS12311 Autologous red blood cells chemically coupled ex vivo with twelve peptides representing the major target antigens in multiple sclerosis, designed to induce antigen-specific immune tolerance in patients with relapsing remitting multiple sclerosis (RRMS) while leaving normal protective immune functions intact.

Companies that use Cellerys

Customer profile

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Cellerys technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Cellerys partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Clinical Trial Sites (4 European Countries)majorStrategic or Co-development Partner · 1 January 2024RED4MS Phase IB/IIA clinical study is conducted in 4 countries across Europe. Multiple clinical investigators and collaborators provide outstanding support for the first-in-human trial.

Scale indicators3 records

Recent moves9 records

Expansion highlights5 records

Cellerys competitors and assessment

Company assessment

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

Cellerys financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cellerys leadership team

Management profile

Number of profiles

Profiles9 records

Cellerys funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cellerys M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellerys

What does Cellerys do?

Cellerys is developing CLS12311, a clinical-stage autologous cell therapy for relapsing remitting multiple sclerosis in which a patient's red blood cells are collected, chemically coupled ex vivo with twelve peptides representing the major target antigens in MS, and reinfused to re-establish antigen-specific immune tolerance. The therapy is being evaluated in the RED4MS Phase Ib/IIa clinical trial across four European countries, with the Phase Ib last-patient visit completed in December 2025.

Is Cellerys a public or private company?

Cellerys is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Cellerys founded?

Cellerys was founded in 2015. It employs 11 to 50 people.

Where is Cellerys based?

Cellerys is headquartered in Schlieren, Switzerland, in the Europe region.

How does Cellerys make money?

One revenue line is on record: CLS12311 Commercialization.

Does Cellerys have an API?

No public API is recorded for Cellerys.

What industry is Cellerys in?

Cellerys's product category is Multiple Sclerosis Therapy. Its primary akta.pro industry code is HLAKAIAF, Multiple Sclerosis & Neuroimmunology, with a secondary code of HLAAABAL, Cell Therapy Enabling Technologies (gene editing, cell engineering, delivery methods). Its NAICS code is 325414 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
startupticker.chNovartis inks partnership agreement with CellerysNovartis and Cellerys signed a long-term partnership to accelerate development of CLS12311, an immune tolerance therapy for multiple sclerosis. Novartis will support the therapy and may acquire Cellerys after Phase 2 trial completion. The drug is currently in Phase 2 investigation.FierceBiotechNovartis pens buyout pact with fellow Swiss native Cellerys, eyeing midstage MS hopefulNovartis signed a collaboration pact with Swiss biotech Cellerys, with an option to acquire the company after a phase 2 trial of its MS drug CLS12311. The deal's financial terms were not disclosed. Novartis has prior MS assets like Kesimpta and Mayzent.YahooNovartis signs deal that could lead to acquisition of Zurich start-up CellerysNovartis signed a collaboration agreement and option to acquire Cellerys, a Zurich-based startup developing a multiple sclerosis therapy. Novartis will support the Phase 2 study of CLS12311 and may acquire Cellerys after Phase 2 completion, with no financial terms disclosed.ReutersNovartis signs deal that could lead to acquisition of Zurich start-up CellerysNovartis has signed a collaboration agreement granting it an option to acquire the Zurich-based startup Cellerys, which is developing a therapy for multiple sclerosis. Novartis will support the development of Cellerys' CLS12311 therapy during its Phase 2 trial, with the acquisition option exercisable upon completion of these trials. No financial details regarding the potential transaction were disclosed.